HAVN Life Sciences Inc. (C:HAVN)

Business Focus: Biotechnology & Medical Research (NEC)

Get the company report for the most recent outlook updated daily

Nov 10, 2023 06:45 am ET

Canadian Investment Regulatory Organization Trading Halt - HAVN

VANCOUVER, BC, Nov. 10, 2023 /CNW/ - The following issues have been halted by CIRO:

Jan 31, 2023 12:54 pm ET

CSE Bulletin: Reinstatement - HAVN Life Sciences Inc. (HAVN)

Toronto, Ontario--(Newsfile Corp. - Le 31 janvier/January 2023) - Effective immediately, HAVN Life Sciences Inc. will be reinstated for trading.

Jan 31, 2023 09:33 am ET

IIROC Trade Resumption - HAVN

VANCOUVER, BC, Jan. 31, 2023 /CNW/ - Trading resumes in:

Jan 09, 2023 10:38 am ET

CSE Bulletin: Suspension - HAVN Life Sciences Inc. (HAVN)

Toronto, Ontario--(Newsfile Corp. - le 09 janvier/January 2023) - Effective immediately, HAVN Life Sciences Inc. is suspended pursuant to CSE Policy 3. The suspension is considered a Regulatory Halt as defined in National Instrument 23-101 Trading Rules. A cease trade order has been issued by the Ontario and British Columbia Securities Commissions.

Jan 09, 2023 06:51 am ET

IIROC Trading Halt - HAVN

VANCOUVER, BC, Jan. 9, 2023 /CNW/ - The following issues have been halted by IIROC:

Oct 31, 2022 03:30 pm ET

The Power Play by The Market Herald Releases New Interviews with SuperBuzz, HAVN Life Sciences and RevoluGROUP Discussing Their Latest News

VANCOUVER, BC / ACCESSWIRE / October 31, 2022 / The Power Play by The Market Herald has announced the release of new interviews with SuperBuzz, HAVN Life Sciences and RevoluGROUP discussing their latest news.

Oct 27, 2022 10:10 am ET

HAVN Life Announces Retail Listing With Loblaws Company Ltd.

The Company's line of plant and mushroom-based natural health products will be available at LCL grocery banners across Canada

Sep 20, 2022 04:31 pm ET

IIROC Trade Resumption - HAVN

VANCOUVER, BC, Sept. 20, 2022 /CNW/ - Trading resumes in:

Sep 20, 2022 03:46 pm ET

HAVN Life Provides Corporate Update

VANCOUVER, BC, Sept. 20, 2022 /CNW/ - HAVN Life Sciences Inc. (CSE: HAVN) (OTC: HAVLF) (FSE: 5NP) (the "Company" or "HAVN Life") announces that the board of directors of the Company (the "Board"), on the advice of the Company's Chief Financial Officer, has determined that the Company is no longer a going concern as it is unable to meet its financial obligations as they come due.

Sep 19, 2022 01:53 pm ET

IIROC Trading Halt - HAVN

VANCOUVER, BC, Sept. 19, 2022 /CNW/ - The following issues have been halted by IIROC:

Aug 18, 2022 05:53 pm ET

HAVN Life Announces the close of the first tranche of its previously announced Financing Commitment by Alpha Blue Ocean and Warrant Amendments‎ and the Issuance of Shares for Debt

VANCOUVER, BC, Aug. 18, 2022 /CNW/ - HAVN Life Sciences Inc. (CSE: HAVN) (OTC: HAVLF) (FSE: 5NP) (the "Company" or "HAVN Life") a biotechnology company pursuing standardized extraction of psychoactive compounds and the development of natural health products, is pleased to announce that it has closed the initial tranche (the "First Tranche") of its financing commitment (the "Financing") by Alpha Blue Ocean ("ABO") that was previously announced on July 21, 2022. The Company intends to use the proceeds from the close of the First Tranche for general working capital purposes.‎

Aug 03, 2022 10:33 am ET

IIROC Trade Resumption - HAVN

VANCOUVER, BC, Aug. 3, 2022 /CNW/ - Trading resumes in:

Aug 03, 2022 09:44 am ET

IIROC Trading Halt - HAVN

VANCOUVER, BC, Aug. 3, 2022 /CNW/ - The following issues have been halted by IIROC:

Aug 02, 2022 12:24 pm ET

CSE Bulletin: Consolidation - HAVN Life Sciences Inc. (HAVN)

Toronto, Ontario--(Newsfile Corp. - Le 2 août/August 2022) - HAVN Life Sciences Inc. has announced a consolidation of its issued and outstanding common shares on the basis of one (1) post-consolidated common share for every thirty (30) pre-consolidated common shares.

Jul 29, 2022 04:30 pm ET

HAVN Life Announces a 30:1 Consolidation of its Common Shares

HAVN Life Sciences Inc. (CSE: HAVN) (OTC: HAVLF) (FSE: 5NP) (the "Company” or "HAVN Life") a biotechnology company pursuing standardized extraction of psychoactive compounds and the development of natural health products, is pleased to announce...

Jul 21, 2022 05:58 pm ET

HAVN Life Announces Financing Commitment of CAD$9,000,000 through the issuance of Convertible Debentures and Warrants

VANCOUVER, BC, July 21, 2022 /CNW/ - HAVN Life Sciences Inc. (CSE: HAVN) (OTC: HAVLF) (FSE: 5NP) (the "Company" or "HAVN Life") a biotechnology company pursuing standardized extraction of psychoactive compounds and the development of natural health products, is pleased to announce that Alpha Blue Ocean ("ABO") is supporting the Company's growth with a CAD$‎‎9,000,000 ‎‎financing arrangement whereby the Company will issue up to $10.6 million principal amount of Convertible Debentures (as defined below), which will include one initial tranche in the aggregate principal amount of $500,000 follo

Jun 28, 2022 07:00 am ET

HAVN Life Enters Supply Agreement with MPB Group Inc.

This new partnership will see the distribution of the Company's standardized, naturally derived, psilocybin containing mushrooms for therapeutic use at Healing Escapes Foundation retreats in Jamaica

Jun 22, 2022 07:00 am ET

HAVN Life To Be Featured On Viewpoint with Dennis Quaid

The Company's segment will be aired on public television networks across the U.S. starting in July, with interviews featuring CEO Tim Moore and the team leading HAVN Life's Research and Development

Jun 22, 2022 07:00 am ET

HAVN Life To Be Featured On Viewpoint with Dennis Quaid

The Company's segment will be aired on public television networks across the U.S. starting in July, with interviews featuring CEO Tim Moore and the team leading HAVN Life's Research and Development

Jun 14, 2022 10:36 am ET

HAVN Life Announces Changes to the Board of Directors

VANCOUVER, BC, June 14, 2022 /CNW/ - HAVN Life Sciences Inc. (CSE: HAVN) (OTC: HAVLF) (FSE: 5NP) (the "Company" or "HAVN Life") announces the departure of Messrs. Victor Neufeld and Dennis Staudt, respectively, as Directors of the Company ("Board"), effective immediately. The Company expresses its appreciation for Mr. Neufeld and Mr. Staudt's services to the Company and wishes them the very best.

Jun 07, 2022 07:00 am ET

HAVN Life Signs Supply Agreement with Licenced Jamaican Cannabis Producer, Green Stripe Naturals Ltd.

This new partnership will see the distribution of The Company's standardized, naturally derived, psilocybin containing mushrooms to local Jamaican dispensaries for legal sale

Jun 06, 2022 11:38 am ET

HAVN Life to Present at Upcoming LD Micro Invitational XII

CEO, Tim Moore will share recent partnership and distribution news and a roadmap for the Company's plans for the next quarter

May 16, 2022 07:52 am ET

HAVN Life Announces Strategic Partnership with Non-Profit Coalition, TheraPsil

Through the Partnership, the Company will seek Health Canada approval to supply naturally-derived psilocybin for legal and therapeutic use via the Special Access Program

May 11, 2022 07:00 am ET

HAVN Life Secures Supply Agreement with Atman Retreats

This new partnership will see the distribution of the Company's standardized, naturally derived, psilocybin containing mushrooms for therapeutic use at Atman retreats in Jamaica

May 02, 2022 08:00 am ET

HAVN Life Ships First White Label Order to Distribution Partner Woke Pharmaceuticals in Australia

The successful shipment of white label natural health products will expand the Company's global retail footprint

Apr 13, 2022 07:00 am ET

HAVN Life Launches the Brain Evolve Series

HAVN Life Sciences Inc. (CSE: HAVN) (OTC: HAVLF) (FSE: 5NP) (the “Company” or “HAVN Life”), a biotechnology company developing natural health products and innovative therapies to support brain health and cognitive function, is pleased to announce...

Mar 22, 2022 08:00 am ET

HAVN Life Expands Supply Agreement with Mycotopia Therapies Inc.

The expanded partnership to include the distribution of functional mushrooms, HAVN Life natural health products and white label products, in addition to its naturally-derived psilocybin compounds

Mar 17, 2022 08:51 am ET

Mycotopia Therapies, Inc. Expands Presence In The Registered Mushroom Sector With HAVN Life Sciences Inc.

Mycotopia Therapies Inc. (OTC Pink: TPIA) (the “Company”), a biopharma company focused on research, technology, and the development of medical psychedelics, announced today plans to expand its supply agreement with Havn Life Sciences (CSE: HAVN)...

Mar 15, 2022 08:00 am ET

HAVN Life Announces Distribution Deal with Jonluca Enterprises Inc.

With this deal, The Company's full line of natural health formulations will now be available across Canada at select health food store locations

Mar 03, 2022 04:58 pm ET

HAVN Life Closes C$2,000,000 Private Placement with U.S. Institutional Investors

/NOT FOR DISSEMINATION IN THE UNITED STATES OR TO U.S. NEWSWIRE SERVICES/

Mar 03, 2022 07:00 am ET

HAVN Life Announces Retail Partnership with Alberta Grocer, Calgary Co-op

The Company's full line of natural health formulations will be available at select locations starting in May

Mar 01, 2022 07:00 am ET

CEO Presenting on the Emerging Growth Conference on March 2 Register Now

EmergingGrowth.com a leading independent small cap media portal with an extensive history of providing unparalleled content for the Emerging Growth Companies and Markets announces the Schedule of the 26th Emerging Growth Conference. The...

Mar 01, 2022 07:00 am ET

HAVN Life Announces CAD$2,000,000 Private Placement with U.S. Institutional Investors

/NOT FOR DISSEMINATION IN THE UNITED STATES OR TO U.S. NEWSWIRE SERVICES./

Mar 01, 2022 07:00 am ET

HAVN Life To Present at Upcoming Emerging Growth Conference 26

CEO Tim Moore will share recent partnership and distribution news and a roadmap for the Company's plans for the next quarter

Feb 28, 2022 07:30 am ET

HAVN Life at Q1 2022 Virtual Investor Summit

CEO Tim Moore will join 80+ other small cap and micro cap companies at leading investor event

Feb 28, 2022 07:00 am ET

HAVN Life Natural Health Products Now Available on Amazon.com

The Company continues to grow its global retail footprint by partnering with the world's largest ecommerce site

Feb 24, 2022 08:00 am ET

HAVN Life Secures Purchase Order for Controlled Substance Sale to Revive Therapeutics Ltd. for Use in Clinical Research

HAVN Life Sciences Inc. (CSE: HAVN) (OTC: HAVLF) (FSE: 5NP) (the “Company” or “HAVN Life”) a biotechnology company pursuing standardized extraction of psychedelic compounds for investigational research as potential APIs to support brain health and...

Feb 24, 2022 07:00 am ET

HAVN Life Secures Purchase Order for Controlled Substance Sale to Revive Therapeutics Ltd. for Use in Clinical Research

The naturally derived GMP psilocybin will be exported through distribution partner Mycrodose Therapeutics Inc. to the University of Wisconsin-Madison, Contract Research Organization for Revive Therapeutics

Feb 22, 2022 07:00 am ET

HAVN Life Announces Termination of Amalgamation Agreement to Acquire Spore Life Sciences

VANCOUVER, BC, Feb. 22, 2022 /CNW/ - Havn Life Sciences Inc. (CSE: HAVN) (OTC: HAVLF) (FSE: 5NP) (the "Company" or "Havn Life"), a biotechnology company developing natural health products and innovative therapies to support brain health and cognitive function, announces that the amalgamation agreement entered into with Spore Life Sciences Inc. ("Spore"), as announced on December 20, 2021, has terminated, and the transactions contemplated thereby are not proceeding.

Feb 17, 2022 05:48 pm ET

HAVN Life Enters into Distribution Agreement with Mycrodose Therapeutics for U.S. Market

The Agreement allows HAVN Life to export naturally derived psilocybin from its Jamaica facility and grows roster of supply partners in the U.S. market

Jan 27, 2022 02:44 pm ET

HAVN Life Session at Psychedelic Capital: Jan 2022 by Microdose

Tim Moore and Michael Zavet to speak on Thursday, January 27 at 4:25pm EST

Jan 26, 2022 03:35 pm ET

HAVN Life Session at Psychedelic Capital: Jan 2022 by Microdose

Tim Moore and Michael Zavet to speak on Thursday, January 27 at 4:25pm EST

Jan 05, 2022 07:00 am ET

HAVN Life Announces Gary Leong's Appointment to Board of Directors

Mr. Leong brings with him a wealth of scientific and regulatory experience

Dec 20, 2021 07:00 am ET

HAVN Life Enters into Definitive Agreement to Acquire Spore Life Sciences Inc.

The Subscription-based Functional Mushroom Company has established a significant consumer base in the U.S.

Dec 13, 2021 07:00 am ET

HAVN Life Successfully Exports Psilocybin from Jamaica Facility into the U.S. for Research Purposes

The Company was able to export naturally derived psilocybin to their California-based Supply Partner, Mycrodose Therapeutics late last week.

Dec 03, 2021 05:00 pm ET

HAVN Life to Present at upcoming SNN Network Canada Virtual Event

CEO Tim Moore to present and host a Q & A for investors on December 8 at 2:30pm EST

Nov 22, 2021 07:00 am ET

HAVN Life Successfully Exports Psilocybin from its Jamaica Facility into Canada

The Company Signs Supply Agreement with Nectar Health Sciences Laboratory Division Inc. to provide naturally derived psilocybin for research and development of therapeutic products

Nov 17, 2021 08:30 am ET

Mycotopia Therapies Announces Plan to Develop Psychedelic Sublingual Tablet to Help Treat Depression

Mycotopia Therapies Inc. (OTC Pink: TPIA) (the “Company”), a biopharma company focused on research, technology, and the development of medical psychedelics, announced today it has initiated plans for a psilocybin-based pharmaceutical program by...

Nov 09, 2021 07:00 am ET

CEO Presenting on the Emerging Growth Conference on November 10 Register Now

Nov 04, 2021 08:30 am ET

Mycotopia Therapies Issues CEO Letter to Stockholders, Reports on Significant Progress and Outlook for 2021

Mycotopia Therapies Inc., (OTC Pink: TPIA) (the “Company”), announced today that Ben Kaplan, President, Chief Executive Officer and Chairman, has issued a letter to Mycotopia Therapies' stockholders. The full text is as follows: To My Fellow...

Nov 04, 2021 08:00 am ET

HAVN Life Enters into Agreement to Distribute its Line of Natural Health Products with Australia's Woke Pharmaceuticals

The Agreement gives Woke Pharmaceuticals exclusive White Label and Distribution rights to HAVN Life products in Australia, New Zealand and China through retail and e-commerce portals

Oct 25, 2021 08:00 am ET

HAVN Life Announces Departure of Rick Brar as Director

VANCOUVER, BC, Oct. 25, 2021 /CNW/ - HAVN Life Sciences Inc. (CSE : HAVN) (OTC: HAVLF) (FSE: 5NP) (the "Company" or "HAVN Life") announces the departure of Mr. Rick Brar as Vice-Chair of the board of directors of the Company ("Board") and as a director of the Company, effective immediately. The Company expresses its appreciation for Mr. Brar's services to the Company and wishes him well in his future endeavours.

Oct 08, 2021 06:00 pm ET

HAVN Life Receives Extension of Six Months to Hold its Annual General Meeting from the Registrar of Companies, British Columbia

VANCOUVER, BC , Oct. 8, 2021 /CNW/ – HAVN Life Sciences Inc. (CSE: HAVN) (OTC: HAVLF) (FSE: 5NP) (the "Company" or "HAVN Life") announces that it has been granted an extension of six months by the Registrar of Companies, to hold its first Annual General Meeting under section 182(4) of the Business Corporations Act (British Columbia). The six months extension is from October 8, 2021, to April 8, 2022.

Oct 07, 2021 08:00 am ET

HAVN Life Files Final Base Shelf Prospectus

VANCOUVER, BC, Oct. 7, 2021 /CNW/ - HAVN Life Sciences Inc. (CSE: HAVN) (OTC: HAVLF) (FSE: 5NP) (the "Company" or "HAVN Life") is pleased to announce that it has filed its final short form base shelf prospectus (the "Final Shelf Prospectus") with the securities commissions in each of the provinces and territories of Canada and received a final receipt in respect thereof.

Oct 01, 2021 09:33 pm ET

HAVN Life Provides an Update on its Operations

VANCOUVER, BC, Oct. 1, 2021 /CNW/ - Havn Life Sciences Inc. (CSE: HAVN) (OTC: HAVLF) (FSE: 5NP) (the "Company" or "Havn Life") provides an update on its operations.

Sep 29, 2021 11:41 am ET

HAVN Life Acquires Bennett's Choice Patented Brain Health and Recovery Formulations

Along with adding new formulations to the Company's natural health product portfolio, founder Matthew Bennett to join HAVN Life as Director of Education

Sep 23, 2021 09:30 am ET

HAVN Life Announces Supply and Distribution MOU with Mycrodose Therapeutics

The partnership is a integral step in the The Company's path to market in the U.S., achieving one of its most important milestones to-date

Sep 21, 2021 08:00 am ET

HAVN Life Announces Distribution Deal with Horizon Grocery + Wellness

VANCOUVER, BC / ACCESSWIRE / September 21, 2021 / Havn Life Sciences Inc. (CSE:HAVN)(OTC PINK:HAVLF)(FSE:5NP) (the "Company" or "Havn Life"), a biotechnology company pursuing standardized extraction of psychedelic compounds for the creation of active pharmaceutical ingredients that support brain health and enhance the capabilities of the mind, is pleased to announce their partnership with Horizon Grocery + Wellness, Western Canada's leading distributor of organic and natural foods, natural personal care items, and nu

Aug 25, 2021 08:00 am ET

HAVN Life Signs Agreement to Supply Psilocybin for Mycotopia Therapies

The partnership will further industry growth for naturally derived psilocybin

Aug 25, 2021 08:00 am ET

Mycotopia Therapies Signs Agreement With Havn Life Sciences For Purchase of Psilocybin SPP

Mycotopia Therapies, Inc. (OTC Pink: TPIA) (the “Company”), a company focused on psychedelic therapies, announced today it has entered into a Psilocybin Supply Agreement with Havn Life Sciences (CSE: HAVN) (OTC Pink: HAVLF). The terms of the...

Aug 11, 2021 07:00 am ET

Havn Life Sciences TO Present at Q3 Investor Summit Virtual Conference

Vancouver, British Columbia--(Newsfile Corp. - August 11, 2021) - Havn Life Sciences Inc. (CSE: HAVN) (OTC Pink: HAVLF) (FSE: 5NP) (the "Company" or "Havn Life"), a biotechnology company developing natural health products and innovative therapies to support brain health and enhance the capabilities of the mind today announced that it will be presenting at the upcoming Q3 Investor Summit Virtual Conference. Details of the presentation are below.

Aug 03, 2021 08:00 am ET

HAVN Life Harvests First Crop of Psilocybin Mushrooms at its Jamaica Facility

HAVN Life will export to Delic Labs in Canada for quality control and testing. This makes HAVN Life the first in the Caribbean Community and Common Market to export psilocybin.

Jul 29, 2021 08:00 am ET

HAVN Life Natural Health Products Now Available on Amazon.ca

With FBA designation, the Company continues to grow its retail footprint by partnering with the world's largest ecommerce site

Jul 27, 2021 08:00 am ET

HAVN Life Signs Agreement to Enable Export of Psilocybin into Canada, the US and Europe

The Agreement with P.A. Benjamin Manufacturing Company whom operates a GMP compliant facility in Jamaica

Jul 08, 2021 08:00 am ET

HAVN Life Signs Exclusive Supply Agreement With Cube Psytech

The Company will supply naturally-derived psilocybin for the development of psilocybin microdosing health products

Jun 29, 2021 08:00 am ET

Allied Corp Signs Psilocybin Manufacturing Agreement To Produce Psilonex™ RX For What We Believe To Be The Largest Known Psilocybin Patient Cohort In The World

Allied Corp. ("Allied" or the “Company”) (OTCQB: ALID) an international medical company focused on creating and providing health solutions to address today’s medical mental health issues is pleased to announce the signing of a supply and...

Jun 29, 2021 08:00 am ET

HAVN Life Sciences Signs Finished Goods Supply Agreement with Allied Health

The Agreement will utilize HAVN Life's fully integrated supply chain model, from the growing of psilocybin through to extraction, compounding, and encapsulation

Jun 08, 2021 08:00 am ET

HAVN Life Announces Retail Partnership with Grocer, Choices Markets

Newly-launched line of natural health products to be available at all locations later this month

Jun 03, 2021 08:00 am ET

HAVN Life Launches New Line of Natural Health Products

Jun 03, 2021 08:00 am ET

HAVN Life Launches New Line of Natural Health Products

Seven New Formulations That Support Brain Health and Immune Function Will Be Available Online and at Select Retail Locations Starting June 3

Jun 02, 2021 08:00 am ET

HAVN Life Completes Acquisition of Clinical Stage IP for Development of Cluster Headache Drug

The Company will seek Orphan Drug Designation to significantly reduce time to market

May 19, 2021 08:00 am ET

HAVN Life Secures Production & Supply Agreement to Expand Retail Product Offerings

Natural Health Products Will Be Manufactured and Packaged at the Company's New Facility

May 17, 2021 08:00 am ET

HAVN Life Enters into Agreement to Acquire Clinical Stage IP for Development of LSD-Derived API for Cluster Headaches

HAVN Life works towards substantiating a patent application and preclinical work

May 14, 2021 08:00 am ET

Havn Life CEO Tim Moore to Appear at Upcoming Q2 Investor SummitHavn Life CEO Tim Moore to Appear at Upcoming Q2 Investor Summit

Havn Life will join 80+ other small cap and micro-cap companies at leading event for investors

May 13, 2021 08:00 am ET

Havn Life Signs Exclusive Supply Agreement with ATMA Journey Centers

Havn Life to supply naturally-derived psilocybin to ATMA Journey Centers in Alberta and Nicoya Peninsula, Costa Rica

May 11, 2021 08:00 am ET

Havn Life Develops New Method for Rapid Psilocybin Testing

Havn Life has completed its analytical work under its Health Canada Section 56 exemption

May 04, 2021 08:00 am ET

Havn Labs Jamaica Facility Now Fully Operational

The Company has started production of its first grow with local partner Hypha Wellness

Apr 08, 2021 08:00 am ET

Havn Life Completes Acquisition of Strategic Manufacturing & Packaging Facility for its Retail Division

The Facility acquisition positions Havn Life to quickly expand its product portfolio and reach additional NHP categories.

Mar 25, 2021 08:00 am ET

Havn Life Sciences Signs LOI to Research and Develop Medical Psilocybin with Jamaican Company Hypha Wellness

Havn Life believes operations can advance its business plan and potentially accelerate production of naturally-derived psilocybin for global medical research.

Mar 19, 2021 08:00 am ET

Havn Life CEO to Present at Zooming with LD, a Leading Platform for Microcap Companies

CEO Tim Moore will appear on Tuesday, March 24th at 8:00 AM PT/ 11:00 AM ET

Mar 16, 2021 08:00 am ET

Havn Life Introduces Industry Leader Jenna Pozar as Chief Operating Officer

Pozar will lead sales, marketing, e-commerce and logistics for Havn Retail

Feb 26, 2021 08:00 am ET

Havn Life Sciences to Host Investor Webcast on March 3, 2021

Attendees will have the opportunity to get the latest updates and participate in Q & A with Havn Life's CEO Tim Moore

Feb 22, 2021 08:00 am ET

Havn Life Announces DTC Eligibility of Its Common Shares in the United States

VANCOUVER, BC / ACCESSWIRE / February 22, 2021 / Havn Life Sciences Inc. (CSE:HAVN)(OTC PINK:HAVLF)(FSE:5NP) (the "Company" or "Havn Life"), a biotechnology company pursuing standardized extraction of psychoactive compounds and the development of natural healthcare products, is pleased to announce today that its common shares are now elig

Feb 17, 2021 08:00 am ET

Havn Life Announces Changes to Board Composition and Departure of Ms. Rasode

VANCOUVER, BC / ACCESSWIRE / February 17, 2021 / Havn Life Sciences Inc. (CSE:HAVN)(OTC PINK:HAVLF)(FSE:5NP) (the "Company" or "Havn Life"), announces the departure of Ms. Barinder Rasode as President and as a director of the Company, effective immediately.

Feb 02, 2021 08:00 am ET

Havn Life Announces Strategic Clinical Trial Partnership with HealthTech Connex Inc.

Havn Life to supply psychedelic compounds for clinical trials launched by neuroscience and technology leader HealthTech Connex

Jan 26, 2021 08:00 am ET

Havn Life Sciences Enters Definitive Agreement to Acquire Strategic Manufacturing & Packaging Facility for its Retail Division

The acquisition is intended to vertically integrate the Company's retail manufacturing capabilities to support the growth of its nutraceutical division and deliver unique products to consumers

Jan 22, 2021 08:00 am ET

Havn Life Sciences Announces Inclusion in First Psychedelic Exchange Traded Fund

VANCOUVER, BC / ACCESSWIRE / January 22, 2021 / Havn Life Sciences Inc. (CSE:HAVN)(OTC PINK:HAVLF)(FSE:5NP) (the "Company" or "Havn Life") a biotechnology company pursuing standardized extraction of psychoactive compounds and the development of natural healthcare products, is pleased to announce that it will be included in the First Psychedelics Exchange Traded Fund ("ETF"). The ETF will begin traded on the

Jan 18, 2021 08:00 am ET

Havn Life to Support Canadian Counterpart of Veterans' Organization, Heroic Hearts

Havn Life to grow its partnership with the US-based veterans' organization by funding and supporting the launch of its Canadian counterpart.

Jan 07, 2021 09:00 am ET

Havn Life Sciences announces closing of C$11.5 million Bought Deal Financing

NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES

Dec 22, 2020 08:00 am ET

Havn Life Sciences and Nesters Market, a Leading Canadian Retailer of Natural Health and Wellness Products, Announce an Authorized Products Listing

Nesters Market retail chain, will list and promote the full range of Havn Life's natural health supplements across its stores in British Columbia in Q1 2021

Dec 18, 2020 06:55 pm ET

Havn Life Sciences Files Preliminary Prospectus in Connection with Bought Deal Equity Financing

NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES

Dec 17, 2020 08:00 am ET

Havn Life Sciences Provides Update on Retail Strategy and Product Development

Havn Retail is on track for its Q1 2021 launch of its initial line of natural health supplements.

Dec 16, 2020 08:00 am ET

Havn Life Sciences Hits Major Milestone with Research Partner, Complex Biotech Discovery Ventures

Havn Research signs contract with CBDV, located at The University of British Columbia's Vancouver campus, to begin Health Canada approved research to analyze psilocybin under Havn Life's Section 56 exemption.

Dec 15, 2020 10:06 am ET

IIROC Trade Resumption - HAVN

VANCOUVER, BC, Dec. 15, 2020 /CNW/ - Trading resumes in:

Dec 15, 2020 10:01 am ET

Havn Life Sciences announces increase in Bought Deal Financing to $10 Million

Havn Life Sciences Inc. (CSE : HAVN) (FSE : 5NP) (the “Company” or “Havn Life”) is pleased to announce that it has entered into an amended agreement with Eight Capital, pursuant to which Eight Capital has now agreed to buy, on a bought deal basis,...

Dec 15, 2020 08:35 am ET

IIROC Trading Halt - HAVN

VANCOUVER, BC, Dec. 15, 2020 /CNW/ - The following issues have been halted by IIROC:

Dec 15, 2020 07:30 am ET

Havn Life Sciences announces $5 million Bought Deal Financing

Havn Life Sciences Inc. (CSE : HAVN) (FSE : 5NP) (the “Company” or “Havn Life”) is pleased to announce that it has entered into an agreement with Eight Capital, pursuant to which Eight Capital has agreed to buy, on a bought deal basis, 4,673,000...

Dec 14, 2020 08:00 am ET

Havn Life Sciences Undertakes One of the First Preclinical Studies on Psilocybin and the Immune System

This is one of the first studies to examine how psilocybin affects the immune system and is a required step to file an application with the Food and Drug Administration (FDA), for a Phase 1 clinical study in humans

Dec 08, 2020 08:00 am ET

Havn Life Sciences to Supply Psychedelic Compounds to Clinical Studies Focused on Veterans and PTSD

Havn Life will collaborate on future clinical studies with Heroic Hearts Project to investigate effects of low-dosage psychoactive compounds on veterans the post-traumatic stress disorder (PTSD).

Dec 03, 2020 08:00 am ET

Havn Life Sciences Partners With Veterans Mental Health Non-Profit, Westwood Institute

Westwood Institute Founder, Dr. Marvin Westwood Will Work With Havn Life's Research Team to Develop Best Practices for Combining Therapy and Psychedelic Interventions for Veterans

Dec 01, 2020 08:00 am ET

Havn Life Attracts International Drug Science and Policy Expert, Joins UK Policy Reform Group

VANCOUVER, BC / ACCESSWIRE / December 1, 2020 / Havn Life Sciences Inc. (CSE:HAVN)(FSE:5NP) (the "Company" or "Havn Life"), a biotechnology company focused on unlocking human potential using evidence-informed research and developing standardized psychoactive compounds derived from plants and fungi, is pleased to announce it has become a voting member of the Conservative Drug Policy Reform Group (CDPRG).

Nov 24, 2020 08:00 am ET

Havn Life Sciences Announces $5.46 Million Warrant Exercise

VANCOUVER, BC / ACCESSWIRE / November 24, 2020 / Havn Life Sciences Inc. (CNSX:HAVN)(FSE:5NP) (the "Company" or "Havn Life") is pleased to announce that 10,927,856 common share purchase warrants ("Warrants") have been exercised ("Exercise"), resulting in proceeds to the Company of $5.46 million. The Warrants had originally been issued by the Company pursuant to a private placement that closed on June 5, 20

Nov 18, 2020 08:00 am ET

Havn Life announces Voluntary Escrow of 6,300,000 Shares

The Voluntary Escrow serves further validates investors belief and support of Havn Life's business plan and future growth strategy

Nov 11, 2020 08:00 am ET

Havn Life Announces Launch of a Range of Natural Health Products

The 7 initial formulations are designed to support and enhance memory and brain function, the immune system, energy levels, and overall wellness while reducing the negative impacts of stress.

Oct 30, 2020 08:00 am ET

Havn Life Sciences to Support the First Modern Psilocybin Depression Study in Germany With MIND Foundation

The research will be led by Prof. Dr. Gerhard Gründer, the only confirmed scientist developing a study to work with psychedelics in Germany since the 1970s

Oct 26, 2020 08:00 am ET

Havn Life Sciences Earns Health Canada Approval for Natural Health Product Formulations

The initial six approved formulations were developed to enhance human performance and cognitive health

Oct 20, 2020 07:00 am ET

Revive Therapeutics Signs Supply Agreement With Havn Life Sciences for Psychedelic Compounds

Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce it has signed a...

Oct 19, 2020 08:00 am ET

Havn Life Sciences Announces Appointment of Dennis Staudt to the Board of Directors & Senior Management Reorganization

VANCOUVER, BC / ACCESSWIRE / October 19, 2020 / Havn Life Sciences Inc. (CSE:HAVN) (FSE:5NP) (the "Company" or "Havn Life"), is pleased to announce that Mr. Dennis Staudt has joined the Company's Board of Directors. Mr. Staudt has over 35 years' experience providing sophisticated business advice, having spent most of his career with PricewaterhouseCoopers LLP ("PwC"), including 22 years as a partner in PwC's Audit and A

Oct 13, 2020 08:00 am ET

Havn Life Applies for Licence to Produce and Sell Psilocybin

The Controlled Drugs and Substances Dealer's Licence will allow Havn Life to supply naturally-derived psilocybin globally to universities, clinical researchers and companies

Oct 05, 2020 08:00 am ET

Havn Life Sciences Announces Appointments of Vic Neufeld as Chairman and Rick Brar as Vice Chairman of the Board of Directors, Respectively, and the Acceleration of Warrants

VANCOUVER, BC / ACCESSWIRE / October 5, 2020 / Havn Life Sciences Inc. (CSE:HAVN)(FSE:5NP) (the "Company" or "Havn Life") is pleased to announce that Mr. Vic Neufeld has been appointed as the Chairman of the Board of Directors of the Company (the "Board"). Mr. Neufeld brings a wealth of knowledge and experience in the Natural Health Food industry, having served as the Chief Executive Officer of Jamieson Laboratories ("Jamieson"), Canada

Oct 01, 2020 08:00 am ET

Havn Life joins UK Psychedelics Working Group with Leading International Scientists

The Working Group Consists of Over 35 Academics, Researchers, and Policy Specialists From Four Countries

Sep 29, 2020 08:35 pm ET

Havn Life Sciences Inc. Reports Q1 Financial Statements

VANCOUVER, BC / ACCESSWIRE / September 29, 2020 / Havn Life Sciences Inc. (CSE:HAVN) (FSE:5NP) (the "Company" or "Havn Life"), is pleased to announce Its financial results for the three month period ended July 31, 2020. Please note that all references to currency are in CDN dollars.

Sep 23, 2020 03:00 am ET

Havn Life Sciences Submits Range of Natural Health Products to Health Canada

Havn Retail, a core pillar of Havn Life continues to reach milestones as the company works towards its launch of a line of retail products

Sep 16, 2020 08:00 am ET

Havn Life Sciences Announces Listing Approval on the Frankfurt Stock Exchange

Havn Life is now cross-listed and trades on both the CSE & FSE

Sep 10, 2020 08:00 am ET

Havn Life Sciences Granted Section 56 Exemption to Begin Scientific Work With Psilocybin

Havn Life will develop methods for safe, standardized, quality- controlled production of medical compounds extracted from the Psilocybe spp. mushroom

Sep 08, 2020 08:00 am ET

Psychedelics Company Havn Life Announces Commencement of Public Trading on the CSE

Havn Life Sciences will trade on the CSE under the Ticker Symbol HAVN

Sep 04, 2020 05:03 pm ET

CSE Bulletin: New Listing - HAVN Life Sciences Inc. (HAVN)

Toronto, Ontario--(Newsfile Corp. - le 4 septembre/September 2020) - The common shares of HAVN Life Sciences Inc. have been approved for listing on the CSE.

Sep 04, 2020 04:15 pm ET

Havn Life Sciences Announces Completion of Acquisition Transaction

VANCOUVER, BC / ACCESSWIRE / September 4, 2020 / Havn Life Sciences Inc. (CSE:HAVN) (the "Company" or "Havn Life"), is pleased to announce that it has successfully completed its acquisition of HAVN Research Inc. ("HAVN Research"), acquiring 100% of the outstanding shares of HAVN Research (the "Acquisition Transaction"). HAVN Research is a biotechnology company engaged in the business of the research and development of psychopharmacological products, including the formulation of standardized psychoactive compounds derived from fungi.

Ad blocking detected

HAVN Life Sciences Inc. (C:HAVN)

Business Focus: Biotechnology & Medical Research (NEC)